NCT00838591 - Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma | Biotech Hunter

Enrollment

176

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Asthma

Interventions

DRUG

MN-221

Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.

DRUG

Placebo

Trial Locations (15)

19141

Albert Einstein Healthcare Network, Philadelphia

23507

Sentara General Hospital, Norfolk

55415

Hennepin County Medical Center, Minneapolis

60153

Loyola University Medical Center, Maywood

63110

Washington University School of Medicine, St Louis

75390

University of Texas Southwestern Medical Center, Dallas

91342

Olive View - UCLA Medical Center, Sylmar

92037

UCSD Medical Center - Thornton Hospital, San Diego

92103

UCSD Medical Center, San Diego

92354

Loma Linda University Medical Center, Loma Linda

02462

Newton - Wellesley Hospital, Newton

01199

Baystate Medical Center, Springfield

07601

Hackensack University Medical Center, Hackensack

45267-0563

University of Cincinnati, Cincinnati

02903

Rhode Island Hospital, Providence